Equities research analysts forecast that Infinity Pharmaceuticals Inc. (NASDAQ:INFI) will post earnings per share (EPS) of ($0.17) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Infinity Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.18) and the highest is ($0.16). Infinity Pharmaceuticals posted earnings per share of ($0.14) in the same quarter last year, which indicates a negative year-over-year growth rate of 21.4%. The company is scheduled to report its next quarterly earnings results on Thursday, March 21st.
On average, analysts expect that Infinity Pharmaceuticals will report full-year earnings of ($0.23) per share for the current fiscal year, with EPS estimates ranging from ($0.25) to ($0.22). For the next financial year, analysts forecast that the business will post earnings of ($0.74) per share, with EPS estimates ranging from ($0.79) to ($0.70). Zacks’ earnings per share calculations are a mean average based on a survey of analysts that follow Infinity Pharmaceuticals.
Infinity Pharmaceuticals (NASDAQ:INFI) last released its quarterly earnings data on Monday, November 5th. The biotechnology company reported $0.23 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.14) by $0.37. The firm had revenue of $22.00 million for the quarter.
Several equities research analysts have recently issued reports on INFI shares. Zacks Investment Research raised shares of Infinity Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.00 price objective for the company in a research report on Tuesday, September 25th. JPMorgan Chase & Co. lowered shares of Infinity Pharmaceuticals from a “neutral” rating to an “underweight” rating in a research note on Monday, November 12th. Finally, Wells Fargo & Co lowered shares of Infinity Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Monday, November 12th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and one has issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $3.50.
In related news, major shareholder Value Fund L. P. Biotechnology purchased 100,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 28th. The shares were purchased at an average cost of $1.30 per share, for a total transaction of $130,000.00. The purchase was disclosed in a document filed with the SEC, which is available through this link. Also, major shareholder Bvf Partners L. P/Il purchased 91,474 shares of the business’s stock in a transaction that occurred on Thursday, November 15th. The shares were bought at an average price of $1.35 per share, for a total transaction of $123,489.90. The disclosure for this purchase can be found here. Insiders have purchased a total of 3,730,634 shares of company stock worth $5,090,055 over the last quarter. 11.45% of the stock is owned by company insiders.
Large investors have recently made changes to their positions in the stock. Algert Global LLC acquired a new stake in Infinity Pharmaceuticals during the 2nd quarter worth $139,000. Acadian Asset Management LLC raised its stake in Infinity Pharmaceuticals by 95.2% during the 2nd quarter. Acadian Asset Management LLC now owns 372,009 shares of the biotechnology company’s stock worth $711,000 after acquiring an additional 181,436 shares in the last quarter. Opaleye Management Inc. acquired a new stake in Infinity Pharmaceuticals during the 3rd quarter worth $745,000. Fosun International Ltd acquired a new stake in Infinity Pharmaceuticals during the 3rd quarter worth $879,000. Finally, Essex Investment Management Co. LLC raised its stake in Infinity Pharmaceuticals by 121.4% during the 3rd quarter. Essex Investment Management Co. LLC now owns 364,401 shares of the biotechnology company’s stock worth $988,000 after acquiring an additional 199,796 shares in the last quarter. Hedge funds and other institutional investors own 52.16% of the company’s stock.
Shares of Infinity Pharmaceuticals stock traded up $0.05 during trading on Friday, hitting $1.29. 289,000 shares of the stock were exchanged, compared to its average volume of 591,134. The stock has a market cap of $68.81 million, a P/E ratio of -1.55 and a beta of 2.51. Infinity Pharmaceuticals has a 12-month low of $1.20 and a 12-month high of $2.92.
Infinity Pharmaceuticals Company Profile
Infinity Pharmaceuticals, Inc, a biopharmaceutical company, develops medicines for people with cancer in the United States. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study.
See Also: Price to Earnings Ratio (PE), For Valuing Stocks
Get a free copy of the Zacks research report on Infinity Pharmaceuticals (INFI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Infinity Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.